

Shouwei Li

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8770056/publications.pdf>

Version: 2024-02-01

27
papers

1,756
citations

430874

18
h-index

501196

28
g-index

29
all docs

29
docs citations

29
times ranked

2391
citing authors

#	ARTICLE	IF	CITATIONS
1	Classification of Gliomas and Germinomas of the Basal Ganglia by Transfer Learning. <i>Frontiers in Oncology</i> , 2022, 12, 844197.	2.8	5
2	Clinical practice guidelines for the management of adult diffuse gliomas. <i>Cancer Letters</i> , 2021, 499, 60-72.	7.2	194
3	Identification of the Prognostic Signatures of Glioma With Different PTEN Status. <i>Frontiers in Oncology</i> , 2021, 11, 633357.	2.8	15
4	LTBP1 plays a potential bridge between depressive disorder and glioblastoma. <i>Journal of Translational Medicine</i> , 2020, 18, 391.	4.4	11
5	A new glioma grading model based on histopathology and Bone Morphogenetic Protein 2 mRNA expression. <i>Scientific Reports</i> , 2020, 10, 18420.	3.3	7
6	Current Opinion on Molecular Characterization for GBM Classification in Guiding Clinical Diagnosis, Prognosis, and Therapy. <i>Frontiers in Molecular Biosciences</i> , 2020, 7, 562798.	3.5	85
7	Transcriptomic Analysis of Glioma Based on IDH Status Identifies ACAA2 as a Prognostic Factor in Lower Grade Glioma. <i>BioMed Research International</i> , 2020, 2020, 1-8.	1.9	5
8	Depressive and anxiety disorders worsen the prognosis of glioblastoma. <i>Aging</i> , 2020, 12, 20095-20110.	3.1	11
9	Genomic landscapes by multiregion sequencing combined with circulation tumor DNA detection contribute to molecular diagnosis in glioblastomas. <i>Aging</i> , 2019, 11, 11224-11243.	3.1	6
10	miR-423-5p contributes to a malignant phenotype and temozolomide chemoresistance in glioblastomas. <i>Neuro-Oncology</i> , 2017, 19, 55-65.	1.2	105
11	CGCG clinical practice guidelines for the management of adult diffuse gliomas. <i>Cancer Letters</i> , 2016, 375, 263-273.	7.2	448
12	Expression of the galectin-9-Tim-3 pathway in glioma tissues is associated with the clinical manifestations of glioma. <i>Oncology Letters</i> , 2016, 11, 1829-1834.	1.8	74
13	Classification based on mutations of <i>TERT</i> promoter and <i>IDH</i> characterizes subtypes in grade II/III gliomas. <i>Neuro-Oncology</i> , 2016, 18, 1099-1108.	1.2	93
14	Radiation combined with temozolomide contraindicated for young adults diagnosed with anaplastic glioma. <i>Oncotarget</i> , 2016, 7, 80091-80100.	1.8	2
15	High expression of CXCR3 is an independent prognostic factor in glioblastoma patients that promotes an invasive phenotype. <i>Journal of Neuro-Oncology</i> , 2015, 122, 43-51.	2.9	29
16	SNORD76, a box C/D snoRNA, acts as a tumor suppressor in glioblastoma. <i>Scientific Reports</i> , 2015, 5, 8588.	3.3	49
17	IDH mutation and MGMT promoter methylation in glioblastoma: results of a prospective registry. <i>Oncotarget</i> , 2015, 6, 40896-40906.	1.8	116
18	Comparison of the clinical efficacy of temozolomide (TMZ) versus nimustine (ACNU)-based chemotherapy in newly diagnosed glioblastoma. <i>Neurosurgical Review</i> , 2014, 37, 73-78.	2.4	21

#	ARTICLE	IF	CITATIONS
19	Whole-genome microRNA expression profiling identifies a microRNA signature as a prognostic biomarker in Chinese patients with primary glioblastoma multiforme. <i>Cancer</i> , 2013, 119, 814-824.	4.1	79
20	Molecular prognostic factors of anaplastic oligodendroglial tumors and its relationship: a single institutional review of 77 patients from China. <i>Neuro-Oncology</i> , 2012, 14, 109-116.	1.2	36
21	miR-181d: a predictive glioblastoma biomarker that downregulates MGMT expression. <i>Neuro-Oncology</i> , 2012, 14, 712-719.	1.2	167
22	Glioblastoma with an oligodendroglioma component: distinct clinical behavior, genetic alterations, and outcome. <i>Neuro-Oncology</i> , 2012, 14, 518-525.	1.2	61
23	Significance of miR-196b in Tumor-Related Epilepsy of Patients with Gliomas. <i>PLoS ONE</i> , 2012, 7, e46218.	2.5	24
24	Correlation between tumor-related seizures and molecular genetic profile in 103 Chinese patients with low-grade gliomas: A preliminary study. <i>Journal of the Neurological Sciences</i> , 2011, 302, 63-67.	0.6	33
25	Inhibition of STAT3 reverses alkylator resistance through modulation of the AKT and β -catenin signaling pathways. <i>Oncology Reports</i> , 2011, 26, 1173-80.	2.6	32
26	Prognostic and predictive value of p53 in low MGMT expressing glioblastoma treated with surgery, radiation and adjuvant temozolomide chemotherapy. <i>Neurological Research</i> , 2010, 32, 690-694.	1.3	16
27	Impact of p53 status to response of temozolomide in low MGMT expression glioblastomas: preliminary results. <i>Neurological Research</i> , 2008, 30, 567-570.	1.3	24